Document Detail

Helicobacter pylori-negative gastritis: prevalence and risk factors.
MedLine Citation:
PMID:  23147524     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: Recent studies using histology alone in select patients have suggested that Helicobacter pylori-negative gastritis may be common. The objective of this study was to investigate the prevalence of H. pylori among individuals with histologic gastritis.
METHODS: Subjects between 40 and 80 years underwent elective esophagogastroduodenoscopy at a VA Medical Center. Gastric biopsies were mapped from seven prespecified sites (two antrum, four corpus, and one cardia) and graded by two gastrointestinal pathologists, using the Updated Sydney System. H. pylori-negative required four criteria: negative triple staining at all seven gastric sites, negative H. pylori culture, negative IgG H. pylori serology, and no previous treatment for H. pylori. Data regarding tobacco smoking, alcohol drinking, nonsteroidal anti-inflammatory drug, and proton pump inhibitor (PPI) use were obtained by questionnaire.
RESULTS: Of the 491 individuals enrolled, 40.7% (200) had gastritis of at least grade 2 in at least one biopsy site or grade 1 in at least two sites. Forty-one (20.5%) had H. pylori-negative gastritis; most (30 or 73.2%) had chronic gastritis, five (12.2%) had active gastritis, and six (14.6%) had both. H. pylori-negative gastritis was approximately equally distributed in the antrum, corpus, and both antrum and corpus. Past and current PPI use was more frequent in H. pylori-negative vs. H. pylori-positive gastritis (68.2% and 53.8%; P=0.06).
CONCLUSIONS: We used multiple methods to define non-H. pylori gastritis and found it in 21% of patients with histologic gastritis. While PPI use is a potential risk factor, the cause or implications of this entity are not known.
Helena Nordenstedt; David Y Graham; Jennifer R Kramer; Massimo Rugge; Gordana Verstovsek; Stephanie Fitzgerald; Abeer Alsarraj; Yasser Shaib; Maria E Velez; Neena Abraham; Bhupinderjit Anand; Rhonda Cole; Hashem B El-Serag
Related Documents :
3753594 - Peptide yy abnormalities in gastrointestinal diseases.
15002824 - Combined terminal ileoscopy and biopsy is superior to small bowel follow-through in det...
21048484 - Probiotic yogurt effects on intestinal flora of patients with chronic liver disease.
7214834 - An analysis of 200 patients with negative small bowel enemas.
25050094 - The use of biologic dmards identifies rheumatoid arthritis patients with more optimisti...
23906444 - Is mesenteric panniculitis truely a paraneoplastic phenomenon? a matched pair analysis.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2012-11-13
Journal Detail:
Title:  The American journal of gastroenterology     Volume:  108     ISSN:  1572-0241     ISO Abbreviation:  Am. J. Gastroenterol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-04     Completed Date:  2013-02-27     Revised Date:  2014-04-15    
Medline Journal Info:
Nlm Unique ID:  0421030     Medline TA:  Am J Gastroenterol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  65-71     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Cross-Sectional Studies
Endoscopy, Digestive System
Gastric Mucosa / microbiology,  pathology
Gastritis / epidemiology,  etiology*,  microbiology,  pathology
Health Surveys
Helicobacter Infections / complications*,  epidemiology,  pathology
Helicobacter pylori / isolation & purification*
Logistic Models
Middle Aged
Multivariate Analysis
Risk Factors
Texas / epidemiology
Grant Support
DK K24-04-107/DK/NIDDK NIH HHS; P30 DK056338/DK/NIDDK NIH HHS; R01 116845//PHS HHS
Comment In:
Am J Gastroenterol. 2013 Jan;108(1):72-4   [PMID:  23287944 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prognostic Value of Serologic and Histologic Markers on Clinical Relapse in Ulcerative Colitis Patie...
Next Document:  Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with...